English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThese four clinical researchers were selected based on the potential of their original research to advance the Academy’s mission of improving patients’ lives through research and innovation:
Ta Chen Peter Chang, MD, associate professor, Bascom Palmer Eye Institute.
Because glaucoma occurs in children at a much lower rate than in adults, ophthalmologists and parents don’t have as much data to guide treatment options. Unlike adults, children are commonly treated with surgery. Dr. Chang will leverage the IRIS Registry database to evaluate treatment options for children, as well as the outcomes of those treatments. This kind of data analysis may also help ease the financial burden of childhood glaucoma, which costs about $21,442 annually per child.
Jennifer Patnaik, PhD, assistant professor, University of Colorado School of Medicine.
Acanthamoeba keratitis is a rare and potentially blinding eye condition. Early diagnosis is a challenge because it’s rare and the symptoms can vary. Additionally, no single, effective chemotherapeutic treatment currently exists. Dr. Patnaik will use the IRIS Registry to better understand and improve diagnosis and treatment of Acanthamoeba keratitis.
Andrew Williams, MD, assistant professor, University of Pittsburgh.
It’s long been known that patients with glaucoma are prone to skipping follow-up exams, which puts them at increased risk for vision loss. But what is the true extent of this problem? Dr. Williams will use the IRIS Registry to conduct a large-scale study to better understand patient adherence with follow-up exams, as well as the effect on their vision.
Nakul Shekhawat, MD, MPH, assistant professor, Johns Hopkins University.
Herpes Zoster, or shingles, can lead to painful and sometimes blinding consequences if it spreads to the nerves in the eye. Dr. Shekhawat will use the IRIS Registry to evaluate the effectiveness of different medications. An analysis based on patient age may help refine or uphold shingles vaccination recommendations.
“These awards are helping to increase the number of vision researchers who have skill and experience in using the IRIS registry as well as to further the key role of big data in the vision science field,” said Brian F. Hofland, PhD, president of RPB. “We are pleased to partner again with the Academy on this effort to enable researchers to address important issues in the diagnosis and treatment of eye diseases.”
Each grant, worth $35,000, provides recipients with a subset of the massive IRIS Registry database for analysis based on their study. Researchers also receive training on how to use the IRIS Registry’s analytic capabilities, as well as $10,000 in direct research funds. Results will be submitted for peer-reviewed publication within six months of study completion.
The Academy and RPB created the grant to help clinical researchers use the power of the Academy’s IRIS Registry database to investigate the causes of both rare and common eye diseases and to uncover innovative approaches to prevention and treatment. The IRIS Registry is the world’s largest medical specialty clinical database, having amassed data on 60 million patients.
“Amassing a rich database is only part of the equation. To reveal patterns of disease and better approaches to their prevention and treatment, you must also ask the right questions,” said David W. Parke II, MD, CEO for the American Academy of Ophthalmology. “This year’s recipients have asked great questions. We look forward to learning the insights their analyses provide.”
Four more grants will be awarded in 2022. The application process will open November 2021. For more information, visit the Academy’s website.
About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.
About Research to Prevent Blindness
Research to Prevent Blindness (RPB) is the leading nonprofit organization supporting eye research directed at the prevention, treatment or eradication of all diseases that damage and destroy sight. As part of this purview, RPB also supports efforts to grow and sustain a robust and diverse vision research community. Since it was founded in 1960 by Dr. Jules Stein, RPB has awarded more than $387 million in research grants to the most talented vision scientists at the nation’s leading medical schools. As a result, RPB has been associated with nearly every major breakthrough in the understanding and treatment of vision loss in the past 50 years. Learn more at www.rpbusa.org.
# # #
